Darapladib
- Generic Name
- Darapladib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H38F4N4O2S
- CAS Number
- 356057-34-6
- Unique Ingredient Identifier
- UI1U1MYH09
- Indication
Investigated for use/treatment in atherosclerosis.
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT02058641
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01873339
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01852565
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28855
- Registration Number
- NCT01636271
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT01506895
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01154114
- Locations
- 🇺🇸
GSK Investigational Site, Orlando, Florida, United States
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 70
- Registration Number
- NCT01067339
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15828
- Registration Number
- NCT00799903
- Locations
- 🇬🇧
GSK Investigational Site, Paisley, United Kingdom
A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00743860
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT00411073
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath